Coskun and Urva (2022, pharmacological description) describe the engineering: modified sequence derived from native GIP, Aib2 and Aib13 substitutions resisting DPP-4, and a C20 diacid fatty-acyl chain grafted to a lysine via a gamma-glutamate linker to extend half-life to approximately 6 days
Weekly updates on weight, appetite, energy levels, and injection details are key
Le smaglutide est une molcule imitant laction du Glucagon-Like Peptide-1 ou GLP-1, une hormone qui rgule le taux de sucre dans le sang (glycmie) et lapptit
Competing Interests The authors report no competing interests
This experiment took place over 56 weeks and was considered a phase 3a, open-label, parallel-group, randomized controlled trial that included 813 participants diagnosed with type 2 diabetes being actively treated with oral antidiabetic drugs
ISBN 978-0-323-99223-7